DexCom Valuation
Is DXCM * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DXCM * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: DXCM * (MX$1485) is trading below our estimate of fair value (MX$1846.6)
Significantly Below Fair Value: DXCM * is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DXCM *?
Key metric: As DXCM * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is DXCM *'s PE Ratio? | |
|---|---|
| PE Ratio | 44.8x |
| Earnings | US$680.80m |
| Market Cap | US$30.51b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.7x |
| Enterprise Value/EBITDA | 36.4x |
| PEG Ratio | 2.7x |
Price to Earnings Ratio vs Peers
How does DXCM *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 34.3x | ||
4543 Terumo | 38.2x | 12.1% | JP¥4.6t |
RMD ResMed | 32.9x | 11.1% | US$36.7b |
IDXX IDEXX Laboratories | 39.9x | 9.8% | US$34.2b |
300760 Shenzhen Mindray Bio-Medical Electronics | 26.3x | 14.7% | CN¥325.4b |
DXCM * DexCom | 44.8x | 16.6% | Mex$30.5b |
Price-To-Earnings vs Peers: DXCM * is expensive based on its Price-To-Earnings Ratio (44.8x) compared to the peer average (34.1x).
Price to Earnings Ratio vs Industry
How does DXCM *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
| 10 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 10 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: DXCM * is expensive based on its Price-To-Earnings Ratio (44.8x) compared to the Global Medical Equipment industry average (28.2x).
Price to Earnings Ratio vs Fair Ratio
What is DXCM *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 44.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate DXCM *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$1,485.00 | Mex$1,935.04 +30.3% | 12.1% | Mex$2,437.50 | Mex$1,523.44 | n/a | 24 |
| Nov ’25 | Mex$1,412.00 | Mex$1,910.67 +35.3% | 11.8% | Mex$2,396.82 | Mex$1,498.01 | n/a | 24 |
| Oct ’25 | n/a | Mex$1,882.81 0% | 15.7% | Mex$2,553.14 | Mex$1,472.96 | n/a | 24 |
| Sep ’25 | n/a | Mex$1,882.81 0% | 15.7% | Mex$2,553.14 | Mex$1,472.96 | n/a | 24 |
| Aug ’25 | Mex$1,306.46 | Mex$1,843.99 +41.1% | 20.6% | Mex$2,853.00 | Mex$1,406.34 | n/a | 24 |
| Jul ’25 | Mex$1,980.00 | Mex$2,750.54 +38.9% | 9.2% | Mex$3,110.24 | Mex$1,921.03 | n/a | 24 |
| Jun ’25 | Mex$1,987.50 | Mex$2,555.19 +28.6% | 9.2% | Mex$2,889.34 | Mex$1,784.59 | n/a | 24 |
| May ’25 | Mex$2,200.00 | Mex$2,578.45 +17.2% | 8.9% | Mex$2,914.92 | Mex$1,800.39 | n/a | 23 |
| Apr ’25 | n/a | Mex$2,460.87 0% | 9.1% | Mex$2,826.11 | Mex$1,745.54 | n/a | 23 |
| Mar ’25 | Mex$1,939.61 | Mex$2,496.31 +28.7% | 8.8% | Mex$2,898.84 | Mex$1,790.46 | n/a | 22 |
| Feb ’25 | Mex$2,099.62 | Mex$2,464.21 +17.4% | 10.2% | Mex$2,944.20 | Mex$1,818.47 | n/a | 20 |
| Jan ’25 | n/a | Mex$2,273.97 0% | 11.1% | Mex$2,742.20 | Mex$1,788.39 | n/a | 22 |
| Dec ’24 | n/a | Mex$2,155.22 0% | 11.4% | Mex$2,664.53 | Mex$1,736.24 | n/a | 22 |
| Nov ’24 | n/a | Mex$2,281.01 0% | 11.8% | Mex$2,806.51 | Mex$1,828.76 | Mex$1,412.00 | 22 |
| Oct ’24 | n/a | Mex$2,494.93 0% | 12.2% | Mex$2,808.83 | Mex$1,615.08 | n/a | 21 |
| Sep ’24 | Mex$1,727.50 | Mex$2,492.38 +44.3% | 10.7% | Mex$2,976.28 | Mex$1,564.67 | n/a | 21 |
| Aug ’24 | Mex$2,097.00 | Mex$2,462.86 +17.4% | 10.6% | Mex$2,930.27 | Mex$1,540.48 | Mex$1,306.46 | 21 |
| Jul ’24 | Mex$2,175.00 | Mex$2,388.26 +9.8% | 10.2% | Mex$2,603.85 | Mex$1,576.02 | Mex$1,980.00 | 20 |
| Jun ’24 | Mex$2,062.12 | Mex$2,436.91 +18.2% | 10.0% | Mex$2,643.74 | Mex$1,621.49 | Mex$1,987.50 | 20 |
| May ’24 | Mex$2,136.01 | Mex$2,479.52 +16.1% | 10.2% | Mex$2,696.99 | Mex$1,654.15 | Mex$2,200.00 | 20 |
| Apr ’24 | n/a | Mex$2,367.45 0% | 10.4% | Mex$2,714.87 | Mex$1,665.12 | n/a | 20 |
| Mar ’24 | n/a | Mex$2,384.42 0% | 10.2% | Mex$2,757.84 | Mex$1,691.48 | Mex$1,939.61 | 19 |
| Feb ’24 | Mex$2,015.59 | Mex$2,385.59 +18.4% | 11.5% | Mex$2,817.63 | Mex$1,728.15 | Mex$2,099.62 | 18 |
| Jan ’24 | Mex$2,123.63 | Mex$2,483.30 +16.9% | 11.9% | Mex$2,934.39 | Mex$1,799.76 | n/a | 17 |
| Dec ’23 | Mex$2,248.00 | Mex$2,399.87 +6.8% | 9.4% | Mex$2,774.02 | Mex$1,822.92 | n/a | 17 |
| Nov ’23 | Mex$2,395.00 | Mex$2,399.87 +0.2% | 9.4% | Mex$2,774.02 | Mex$1,822.92 | n/a | 17 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.